- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF(PILL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PILL
11/20/2026: PILL (1-star) is currently NOT-A-BUY. Pass it for now.
ETF PILL provides 3x daily leveraged exposure to an equal-weighted index of U.S. pharmaceutical companies primarily via swap agreements and derivatives. Its main strength lies in offering targeted high-beta exposure for tactical swing traders without requiring margin accounts. The fund functions strictly as a short-term trading vehicle rather than a long-term investment option. Its primary risks stem from daily compounding decay, high volatility, and concentration within the pharmaceutical industry. It suits experienced short-term momentum traders who actively monitor sector catalysts and exit positions rapidly.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Long-term growth strategies clash with the daily-reset mechanics and decay risk of leveraged products. |
| Momentum investor | Strong fit while signal remains positive | Active momentum traders can exploit short-term bullish trends in the pharmaceutical sector using triple daily leverage. |
| Value investor | Weak fit | The fund's tactical derivative structure is unsuited for traditional fundamental valuation investing. |
| Dividend/Income investor | Weak fit | The ETF distributes negligible dividend income and focuses strictly on capital movement. |
| Low-risk investor | Weak fit | Extreme volatility and daily compounding risk make this fund unsuitable for risk-averse portfolios. |
Investor Profile
Ideal Investor Profile
Active tactical traders, day traders, and sophisticated market participants seeking short-term leveraged exposure to pharmaceutical catalysts.
Suitability
Best suited exclusively for short-term, intraday, or swing trading strategies, and strongly inappropriate for buy-and-hold or long-term investors.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Amplified 3x daily swings expose investors to rapid, severe capital losses. |
| Market risk | High | Vulnerable to sudden regulatory, legal, or clinical setbacks in the pharmaceutical sector. |
| Concentration | High | Focused entirely on U.S. pharmaceutical companies, limiting diversification. |
| Tracking/expense | Medium / high | Compounding effects and a 0.98% expense ratio cause long-term returns to deviate from 3x index performance. |
| Liquidity | Medium | Moderate trading volumes can impact execution costs during stressful market events. |
| Business/sector quality | Medium | While underlying pharma firms are often stable cash-generators, the wrapper itself is a speculative instrument. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
PILL exhibits exceptionally high historical volatility due to its 3x daily leverage objective applied to a cyclical and news-driven sector.
Market Risk
Subject to intense sector-specific risks, including drug pipeline failures, regulatory scrutiny, patent expirations, and political pricing pressures.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | S&P Pharmaceuticals Select Industry Index — seeks 3x daily return | 85 | Provides the primary financial derivatives and swap exposure required to deliver triple daily index performance. |
| Sector | U.S. Pharmaceutical Equities Basket | 14 | Holds underlying physical stocks from the index to support derivative tracking and fund liquidity. |
| Cash/collateral | Cash and U.S. Treasury Securities | 1 | Maintains a minor collateral buffer to support daily margin and operational requirements. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type ETF | Historic Profit 108.7% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

